{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:08:08Z","timestamp":1762999688083,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007497","name":"Biosense Webster","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To compare patient characteristics, safety and efficacy of catheter ablation of supraventricular tachycardia (SVT) in patients with and without structural heart disease (SHD) enrolled in the German ablation registry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>From January 2007 until January 2010, a total of 12,536 patients (37.2% with known SHD) were enrolled and followed for at least one year. Patients with SHD more often underwent ablation for atrial flutter (45.8% vs. 20.9%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), whereas patients without SHD more often underwent ablation for atrioventricular nodal reentrant tachycardia (30.2% vs. 11.8%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) or atrioventricular reentrant tachycardia (9.1% vs. 1.6%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Atrial fibrillation catheter ablation procedures were performed in a similar proportion of patients with and without SHD (38.1% vs. 36.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.21).<\/jats:p>\n                <jats:p>Overall, periprocedural success rate was high in both groups. Death, myocardial infarction or stroke occurred in 0.2% and 0.1% of patients with and without SHD (<jats:italic>p<\/jats:italic>\u2009=\u20090.066). Major non-fatal complications prior to discharge were rare and did not differ significantly between patients with and without SHD (0.5% vs. 0.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.34). Kaplan\u2013Meier mortality estimate at 1\u00a0year demonstrated a significant mortality increase in patients with SHD (2.6% versus 0.7%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with and without SHD undergoing SVT ablation exhibit similar success rates and low major complication rates, despite disadvantageous baseline characteristics in SHD patients. These data highlight the safety and efficacy of SVT ablation in patients with and without SHD. Nevertheless Kaplan\u2013Meier mortality estimates at 1\u00a0year demonstrate a significant mortality increase in patients with SHD, highlighting the importance of treating the underlying condition and reliable anticoagulation if indicated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00392-021-01878-z","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T06:27:20Z","timestamp":1623220040000},"page":"522-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Catheter ablation of supraventricular tachycardia in patients with and without structural heart disease: insights from the German ablation registry"],"prefix":"10.1007","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-6791","authenticated-orcid":false,"given":"Charlotte","family":"Eitel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00fcseyin","family":"Ince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Brachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Heinz","family":"Kuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan G.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen","family":"Tebbenjohanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leon","family":"Iden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Straube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Hochadel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Senges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland R.","family":"Tilz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"1878_CR1","first-page":"1442","volume":"39","author":"DG Katritsis","year":"2018","unstructured":"Katritsis DG, Boriani G, Cosio FG et al (2018) European heart rhythm association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Eur Heart J 39:1442\u20131445","journal-title":"Eur Heart J"},{"key":"1878_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","volume":"41","author":"J Brugada","year":"2020","unstructured":"Brugada J, Katritsis DG, Arbelo E et al (2020) 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. The task force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 41:655\u2013720","journal-title":"Eur Heart J"},{"key":"1878_CR3","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/eurheartj\/ehx101","volume":"38","author":"J Brachmann","year":"2017","unstructured":"Brachmann J, Lewalter T, Kuck KH et al (2017) Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry. Eur Heart J 38:1317\u20131326","journal-title":"Eur Heart J"},{"key":"1878_CR4","doi-asserted-by":"publisher","first-page":"e17333","DOI":"10.1097\/MD.0000000000017333","volume":"98","author":"A Morka","year":"2019","unstructured":"Morka A, Sledz J, Deutsch K et al (2019) Feasibility and performance of catheter ablation with zero-fluoroscopy approach for regular supraventricular tachycardia in patients with structural and\/or congenital heart disease. Medicine 98:e17333","journal-title":"Medicine"},{"key":"1878_CR5","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.recesp.2012.06.008","volume":"65","author":"E Diaz-Infante","year":"2012","unstructured":"Diaz-Infante E, Macias Gallego A, Ferrero De Loma-Osorio A (2012) Spanish catheter ablation registry. 11th official report of the Spanish Society of Cardiology Working Group on electrophysiology and arrhythmias (2011). Rev Esp Cardiol 65:928\u2013936","journal-title":"Rev Esp Cardiol"},{"key":"1878_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/europace\/eun298","volume":"11","author":"M Kesek","year":"2009","unstructured":"Kesek M (2009) Ablation procedures in Sweden during 2007: results from the Swedish catheter ablation registry. Europace 11:152\u2013154","journal-title":"Europace"},{"key":"1878_CR7","doi-asserted-by":"publisher","first-page":"67B","DOI":"10.1016\/S0828-282X(07)71013-9","volume":"23","author":"GE O'hara","year":"2007","unstructured":"O\u2019hara GE, Philippon F, Champagne J et al (2007) Catheter ablation for cardiac arrhythmias: a 14-year experience with 5330 consecutive patients at the Quebec Heart Institute, Laval Hospital. Can J Cardiol 23:67B-70B","journal-title":"Can J Cardiol"},{"key":"1878_CR8","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/hc4601.097997","volume":"104","author":"I Olivotto","year":"2001","unstructured":"Olivotto I, Cecchi F, Casey SA et al (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104:2517\u20132524","journal-title":"Circulation"},{"key":"1878_CR9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/jce.12982","volume":"27","author":"I Wilke","year":"2016","unstructured":"Wilke I, Witzel K, Munch J et al (2016) High incidence of de novo and subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy and cardiac rhythm management device. J Cardiovasc Electrophysiol 27:779\u2013784","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1878_CR10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/CIRCEP.113.000339","volume":"6","author":"P Santangeli","year":"2013","unstructured":"Santangeli P, Di Biase L, Themistoclakis S et al (2013) Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence. Circ Arrhythm Electrophysiol 6:1089\u20131094","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1878_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00392-019-01411-3","volume":"108","author":"C Eitel","year":"2019","unstructured":"Eitel C, Ince H, Brachmann J et al (2019) Atrial fibrillation ablation strategies and outcome in patients with heart failure: insights from the German ablation registry. Clin Res Cardiol 108:815\u2013823","journal-title":"Clin Res Cardiol"},{"key":"1878_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00392-018-1368-2","volume":"108","author":"K Wasmer","year":"2019","unstructured":"Wasmer K, Hochadel M, Wieneke H et al (2019) Long-term symptom improvement and patient satisfaction after AV-node ablation vs. pulmonary vein isolation for symptomatic atrial fibrillation: results from the German Ablation Registry. Clin Res Cardiol 108:395\u2013401","journal-title":"Clin Res Cardiol"},{"key":"1878_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1707855","volume":"378","author":"NF Marrouche","year":"2018","unstructured":"Marrouche NF, Brachmann J, Andresen D et al (2018) Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378:417\u2013427","journal-title":"N Engl J Med"},{"key":"1878_CR14","first-page":"e007731","volume":"12","author":"KH Kuck","year":"2019","unstructured":"Kuck KH, Merkely B, Zahn R et al (2019) Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. Circulation 12:e007731","journal-title":"Circulation"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01878-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01878-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01878-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T08:10:07Z","timestamp":1651219807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01878-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1878"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01878-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"type":"print","value":"1861-0684"},{"type":"electronic","value":"1861-0692"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CE received travel grants from Biosense Webster, Medtronic, Biotronik, Abbott and Daiichi Sankyo, speaker\u2018s honoraria from Biosense Webster, Medtronic, Abbott, Sentrheart and Daiichi Sankyo. Outside the submitted work, FS received honoraria for lectures from Bristol Meyer Squibb and Astra Zeneca, and travel support and honoraria for lectures from Medtronic. RRT is a consultant of Biosense Webster, Biotronik and Boston Scientific and received Speaker\u2019s Bureau Honoraria from Biosense Webster, Medtronic, Boston Scientific and Abbot Medical. All other authors have no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}